Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart Perioperative vs Adjuvant in Resectable NSCLC
NCT06109402Phase 2Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Dec 2023
- Primary completion
- Nov 2030
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06109402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06109402.